journal article·2021-03

Metformin Mediated PD‐L1 Downregulation in Combination with Photodynamic‐Immunotherapy for Treatment of Breast Cancer

Chuan Hu, Xueqin He, Yuxiu Chen, Xiaotong Yang, Lin Qin, Ting Lei, Yang Zhou, Tao Gong, Yuan Huang, Huile Gao

Advanced Functional Materials· Volume 31· Issue 11
Publisher page

Abstract

Abstract Intelligent nanomaterials open up new avenues for realizing safer and more effective combination immunotherapy. Herein, a kind of simple enzymatically cleavable self‐delivery nanoparticles (MA‐pepA‐Ce6 NPs) is developed by conjugating acidic‐sensitive small‐molecule programmed cell death ligand 1 (PD‐L1) inhibitor (Metformin, MET) with photosensitizer (chlorin e6, Ce6) through matrix metalloproteinase‐2 (MMP‐2) cleavable peptide (GPLGVRGDK, pepA). Noticeably, these self‐delivery peptide‐based NPs can circumvent the controversial biosafety facing nanomaterials. Moreover, MA‐pepA‐Ce6 NPs are degraded by overexpressed MMP‐2 in tumor microenvironment (TME) and expose the VRGDK‐Ce6. The exposed VRGDK‐Ce6 shows superior targeting ability towards integrin αvβ3 receptor, ensuring sufficient accumulation and laser‐activated robust antitumor immune effects. Remarkably, the released MET in tumor microenvironment hampers the PD‐L1 expression and augments the antitumor immune response elicited by photodynamics therapy (PDT), thus significantly improving therapeutic outcomes. Overall, this study offers a potential appealing paradigm of synergistic PDT‐triggered immunotherapy by revealing MET‐mediated PD‐L1 downregulation to achieve tumor eradication.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Peptidase Inhibition and Analysis · Click Chemistry and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Key Laboratory of Drug‐Targeting and Drug Delivery System of the Education Ministry Sichuan Engineering Laboratory for Plant‐Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology West China School of Pharmacy Sichuan University No. 17, Block 3, Southern Renmin Road Chengdu 610041 P. R. China

Funding

National Natural Science Foundation of China · Fundamental Research Funds for the Central Universities

References (31)

Show source-provided references
1. 10.1038/nature1067310.1038/nature10673 ↗
2. 10.3389/fonc.2014.0038510.3389/fonc.2014.00385 ↗
3. 10.1038/nature1395410.1038/nature13954 ↗
4. 10.1126/science.aad009510.1126/science.aad0095 ↗
5. 10.1038/nm.432110.1038/nm.4321 ↗
6. 10.1016/j.molcel.2018.07.03010.1016/j.molcel.2018.07.030 ↗
7. 10.1038/nrendo.2013.25610.1038/nrendo.2013.256 ↗
8. 10.1038/s41573-018-0007-y10.1038/s41573-018-0007-y ↗
9. 10.1038/nrc189410.1038/nrc1894 ↗
10. 10.1158/1078-0432.CCR-09-289110.1158/1078-0432.CCR-09-2891 ↗
11. 10.1016/j.cclet.2020.02.00710.1016/j.cclet.2020.02.007 ↗
12. 10.1021/acs.nanolett.9b0292310.1021/acs.nanolett.9b02923 ↗
13. 10.1002/adfm.20180846210.1002/adfm.201808462 ↗
14. 10.1002/adma.20190092710.1002/adma.201900927 ↗
15. 10.1038/nrd259110.1038/nrd2591 ↗
16. 10.1039/C8CS00473K10.1039/C8CS00473K ↗
17. 10.1016/j.apsb.2020.05.00810.1016/j.apsb.2020.05.008 ↗
18. 10.1002/adma.20150150210.1002/adma.201501502 ↗
19. 10.1021/acs.bioconjchem.7b0033010.1021/acs.bioconjchem.7b00330 ↗
20. 10.1002/advs.20180022910.1002/advs.201800229 ↗
21. 10.1016/j.apsb.2020.07.01310.1016/j.apsb.2020.07.013 ↗
22. 10.1016/j.cell.2010.03.01510.1016/j.cell.2010.03.015 ↗
23. 10.1080/02652048.2017.134387310.1080/02652048.2017.1343873 ↗
24. 10.1039/C5NR01408E10.1039/C5NR01408E ↗
25. 10.1016/j.addr.2010.04.00910.1016/j.addr.2010.04.009 ↗
26. 10.1021/acsami.7b0230310.1021/acsami.7b02303 ↗
27. 10.1039/C8NR01184B10.1039/C8NR01184B ↗
28. 10.1038/nri254510.1038/nri2545 ↗
29. 10.1146/annurev-immunol-032712-10000810.1146/annurev-immunol-032712-100008 ↗
30. 10.1002/mabi.20080006510.1002/mabi.200800065 ↗
31. 10.1016/j.biomaterials.2018.03.04610.1016/j.biomaterials.2018.03.046 ↗